ACCREDITATION DOCUMENT
- F-06/02
- Issue Date: 10/08/15
- Rev. No: 07
- LAB-62
Accreditation No: LAB-62
Awarded to
Saffron Pharmaceutical Pvt. Ltd., Quality Control Laboratory .
19-Km Sheikhupura Road, Faisalabad, Pakistan
The scope of accreditation is in accordance with the standard specifications outlined in the
following page(s) of this document. The accredited scope shall be visible and legible in areas
such as customer service, sample-receiving section etc. and shall not mislead its users.
The accreditation was first time granted on 08/4/2013 by Pakistan National
Accreditation Council
The laboratory complies with the requirements of ISO/IEC 17025:2017.
The accreditation requires regular surveillance, and is valid until 22/9/2025.
The decision of accreditation made by Pakistan National Accreditation Council
implies that the organization has been found to fulfill the requirements for
accreditation within the scope.
The organization however, itself is responsible for the results of performed
measurements/tests.
PAKISTAN NATIONAL ACCREDITATION COUNCIL
- 22/9/2025
- Date
- SD
- Director General
ACCREDITATION DOCUMENT
- F-06/02
- Issue Date: 10/08/15
- Rev. No: 07
- LAB-0LAB-62
Testing Laboratory
Accreditation Scope of
Saffron Pharmaceutical Pvt. Ltd., Quality Control Laboratory
19-Km Sheikhupura Road, Faisalabad, Pakistan
| S# | Materials/Products Tested | Testing Field (e.g. environmental testing or mechanical testing) | Types of Tests/ properties measured | Reference to Standardized method |
|---|---|---|---|---|
| 1 | Locus Infusion 500mg/100mL | Pharmaceuticals Testing | Assay | Saffron Specification |
| 2 | Locus Infusion 500mg/100mL | Pharmaceuticals Testing | Osmolality | Saffron Specification |
| 3 | Locus Infusion 500mg/100mL | Pharmaceuticals Testing | Particulate Matter | USP 2021 |
| 4 | Bezel 500mcg Tablet | Pharmaceuticals Testing | Disintegration Test | USP 2021 <701> |
| 5 | Bezel 500mcg Tablet | Pharmaceuticals Testing | Identification | USP2021 |
| 6 | Bezel 500mcg Tablet | Pharmaceuticals Testing | Uniformity of weight | USP2021 |
| 7 | Lucid 500mg Tablet | Pharmaceuticals Testing | Dissolution | USP2021 |
| 8 | Locus 500mg Tablet | Pharmaceuticals Testing | Assay | USP2021 |
| 9 | Locus 500mg Tablet | Pharmaceuticals Testing | Disintegration Test | USP2021 <701> Disintegration |
| 10 | Locus 500mg Tablet | Pharmaceuticals Testing | Identification | USP2021 |
| 11 | Locus 500mg Tablet | Pharmaceuticals Testing | Uniformity of weight | USP2021 <905> Uniformity of dosage unit |
| 12 | Bezel Injection 500mcg/mL | Pharmaceuticals Testing | Particulate Mattle | USP 2021 |
| 13 | Terbisil 1% w/w Lotion | Pharmaceuticals Testing | pH | Innovator Specs. |
| 14 | Terbisil 1% w/w Spray | Pharmaceuticals Testing | Identification Test | JP Specs. 18th edition |
| 15 | Terbisil 1% w/w Spray | Pharmaceuticals Testing | pH | Innovator Specs. |
| 16 | Lucid 250mg Tablet | Pharmaceuticals Testing | Uniformity of weight | USP2021<905> Uniformity of dosage unit |
| 17 | Lucid 500mg Tablet | Pharmaceuticals Testing | Assay | USP2021, in-house alternate method |
| 18 | Lucid 500mg Tablet | Pharmaceuticals Testing | Disintegration Test | USP2021<701> Disintegration |
- 22/9/2025
- Date
- SD
- Director